Nykredit A S Buys New Shares in Axon Enterprise, Inc $AXON

Nykredit A S bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 37,491 shares of the biotechnology company's stock, valued at approximately $21,018,000.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in Axon Enterprise in the 4th quarter valued at about $480,000. NewEdge Advisors LLC grew its position in shares of Axon Enterprise by 41.1% during the first quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company's stock worth $1,207,000 after buying an additional 668 shares in the last quarter. Empowered Funds LLC grew its position in shares of Axon Enterprise by 8.4% during the first quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company's stock worth $1,067,000 after buying an additional 157 shares in the last quarter. Woodline Partners LP increased its stake in shares of Axon Enterprise by 40.6% during the first quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company's stock worth $3,646,000 after buying an additional 2,003 shares during the period. Finally, Sivia Capital Partners LLC purchased a new stake in shares of Axon Enterprise during the second quarter worth approximately $284,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on AXON shares. Citizens Jmp reiterated a "market outperform" rating and issued a $700.00 price target on shares of Axon Enterprise in a research note on Thursday, June 25th. Argus increased their price objective on shares of Axon Enterprise from $460.00 to $600.00 and gave the company a "buy" rating in a research report on Thursday. Needham & Company LLC restated a "buy" rating on shares of Axon Enterprise in a report on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of Axon Enterprise from $750.00 to $755.00 and gave the stock an "overweight" rating in a research report on Thursday, May 7th. Finally, Piper Sandler boosted their target price on shares of Axon Enterprise from $724.00 to $732.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $721.57.

Axon Enterprise Stock Performance

Shares of AXON opened at $538.15 on Friday. The stock has a 50 day moving average price of $568.46 and a 200 day moving average price of $486.03. The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $43.72 billion, a price-to-earnings ratio of 223.30, a price-to-earnings-growth ratio of 8.23 and a beta of 1.40. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $792.16.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The company had revenue of $904.39 million for the quarter, compared to analysts' expectations of $876.42 million. During the same quarter last year, the company earned $2.12 earnings per share. The firm's revenue for the quarter was up 35.3% on a year-over-year basis. Research analysts predict that Axon Enterprise, Inc will post 2.04 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Patrick Smith sold 9,930 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $548.77, for a total value of $5,449,286.10. Following the completion of the sale, the chief executive officer directly owned 3,031,067 shares of the company's stock, valued at $1,663,358,637.59. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 16,775 shares of the company's stock in a transaction on Monday, August 31st. The shares were sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the completion of the transaction, the president owned 296,974 shares of the company's stock, valued at $170,590,774.82. This represents a 5.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 56,380 shares of company stock worth $32,582,366 in the last ninety days. 4.20% of the stock is owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source